Voyager Therapeutics Inc. ( (VYGR) ) has released its Q3 earnings. Here is a breakdown of the information Voyager Therapeutics Inc. presented to its investors.
Voyager Therapeutics, Inc., a biotechnology company specializing in neurogenetic medicines, focuses on advancing treatments for neurological diseases such as Alzheimer’s, ALS, and Parkinson’s using their TRACER™ AAV capsid discovery platform.
In its third quarter 2024 earnings report, Voyager Therapeutics highlighted significant progress in its clinical trials, partnerships, and financials, positioning the company strongly for future developments. Key advancements were made in their anti-tau antibody program for Alzheimer’s disease, and new collaborations were forged.
Voyager reported a substantial increase in collaboration revenue, reaching $24.6 million compared to $4.6 million the previous year, attributed to agreements with partners like Novartis and Neurocrine. Despite a net loss of $9.0 million, this marks an improvement from the $25.9 million loss in the same period last year, with research and development expenditures rising to $30.2 million.
Strategic partnerships and pipeline expansions were notable, with a new TRACER™ capsid licensed to Novartis and the selection of a new gene therapy development candidate with Neurocrine. These collaborations are expected to yield significant milestone payments and royalties in the future.
Looking forward, Voyager remains optimistic about its cash runway extending into 2027, with management confident in advancing their clinical trials and IND filings for various CNS gene therapies, setting a robust stage for continued growth and innovation in treating neurological disorders.
